Perrigo is a pure-play consumer healthcare product manufacturer and distributor. In North America (two-thirds of total sales), the firm's product mix centers on private-label consumer health goods sold to major retailers such as Walmart, Amazon.com, Costco, and CVS. It plays in a number of over-the-counter categories including pain, skincare, women's health, and nutrition. Perrigo also competes in Europe, Australia, and parts of Asia, where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
Last trade$15.92
Day change-$0.26 (-1.61%)
Day range$15.82 – $16.57
Volume745,229
Market cap$2.25B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$2.25B
Price / earnings
—
Price / book
0.92×
Price / sales
0.55×
EV / sales
1.25×
EV / EBITDA
9.61×
Profitability
Earnings per share
-$12.75
Return on assets
-23.64%
Return on equity
-72.51%
Dividend yield
7.13%
Liquidity and leverage
Debt / equity
1.35×
Current ratio
2.35×
Quick ratio
1.36×
Cash ratio
0.43×
Cash flow
Price / cash flow
9.33×
Price / free cash flow
13.35×
Free cash flow
$168.2M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for PRGO, quarterly periods
Line item
Q3 FY2026 Sep 26, 2026
Q2 FY2026 Jun 27, 2026
Q1 FY2026 Mar 28, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 27, 2025
Q2 FY2025 Jun 28, 2025
Q1 FY2025 Mar 29, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$988.6M
$1.02B
$969.2M
$1.11B
$1.04B
$1.06B
$1.04B
$1.14B
Cost of revenue
$667.8M
$708.9M
$643.7M
$747.4M
$666.2M
$693.4M
$651.6M
$752.4M
Gross profit
$320.8M
$313.9M
$325.5M
$362.2M
$377.1M
$362.9M
$392.3M
$385.9M
Selling, general and administrative
$271.7M
$251.2M
$267.3M
$255.9M
$245.7M
$273.1M
$281.2M
$234.8M
Research and development
$21.9M
$23.7M
$24.6M
$21.8M
$24.9M
$22M
$26.7M
$27.8M
Total operating expenses
$297.7M
$290.3M
$697.8M
$1.65B
$304.5M
$317.5M
$345.4M
$271.7M
Operating income
$23.1M
$23.6M
-$372.3M
-$1.29B
$72.6M
$45.4M
$46.9M
$114.2M
Interest expense
-$37.9M
-$38.4M
-$40.8M
-$43.3M
-$40.6M
-$39.6M
-$39M
-$43.1M
Income before taxes
-$18.1M
$105.4M
-$408.5M
-$1.33B
$22.4M
$3.2M
$8.3M
$70M
Income taxes
-$3.8M
$16.9M
-$18.7M
$82.9M
$9.7M
$3.7M
$8.2M
$111.5M
Net income
-$27.5M
$74.5M
-$398.5M
-$1.42B
$7.5M
-$8.4M
-$6.4M
-$44.5M
Net income attributable to common shareholders
-$27.5M
$74.5M
-$398.5M
-$1.42B
$7.5M
-$8.4M
-$6.4M
-$44.5M
EBITDA
$109M
$134.8M
$116.9M
$170.3M
$178.8M
$141.9M
$159.3M
$245.1M
Basic earnings per share
-$0.20
$0.54
-$2.87
-$10.16
$0.05
-$0.06
-$0.05
-$0.32
Diluted earnings per share
-$0.20
$0.53
-$2.87
-$10.19
$0.05
-$0.06
-$0.05
-$0.32
Recent news
Company coverage with links to the original publishers.
Perrigo announced an agreement to divest its infant formula business to streamline operations and improve margins. The company is capitalizing on e-commerce momentum, with online sales reaching 22% of U.S. volume (up from 13% in 2022). Despite cautious retailer ordering, Perrigo gained market share in store brands and European health products, positioning itself as a more focused consumer self-care company.
Perrigo (PRGO) reported Q3 2026 earnings of $0.60 per share, beating consensus estimates of $0.56, but revenues missed expectations at $988.6 million versus $990.2 million consensus. Despite outperforming the S&P 500 by 2.2% year-to-date, the company received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends. The Medical-Products industry ranks in the bottom 37% of Zacks industries, suggesting headwinds ahead.
Stryker reported Q3 2026 earnings of $3.52 per share, missing consensus estimates of $3.56, with revenues of $6.52 billion also falling short of expectations. The company received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revisions. Stryker has underperformed the S&P 500 by 26.6% year-to-date, and the Medical Products industry ranks in the bottom 38% of Zacks industries.
Perrigo is expected to report Q3 2026 earnings of $0.56 per share (down 30% YoY) and revenues of $990.45 million (down 5.1% YoY) on November 4. With a negative Earnings ESP of -11.24% and a Zacks Rank #4, the stock appears unlikely to beat consensus estimates despite a strong historical track record of beating expectations in 3 of the last 4 quarters.
Abbott reported Q3 2026 earnings of $1.42 per share, missing the consensus estimate of $1.43, though revenues of $13.01 billion exceeded expectations. The company has underperformed the S&P 500 by 18.2% year-to-date. Despite the earnings miss, Abbott maintains a Zacks Rank #2 (Buy) rating based on favorable estimate revision trends. The Medical-Products industry ranks in the bottom 36% of Zacks industries.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
Declared upcoming dividend$0.29 per share
Declared
Oct 29, 2026
Ex-dividend
Nov 27, 2026
Pay date
Dec 15, 2026
Ex-dividend
Amount / share
Pay date
Type
Aug 28, 2026
$0.29
Sep 15, 2026
recurring
May 29, 2026
$0.29
Jun 16, 2026
recurring
Mar 2, 2026
$0.29
Mar 24, 2026
recurring
Nov 28, 2025
$0.29
Dec 16, 2025
recurring
Aug 29, 2025
$0.29
Sep 16, 2025
recurring
Stock splits
Historical share-structure events and their execution dates.